Does Orencia Increase Risk of Lung Infections?
Orencia (abatacept) suppresses T-cell activation, which can impair immune responses and raise infection risks, including respiratory ones. Clinical trials and post-marketing data show higher rates of serious infections with Orencia compared to placebo, with upper respiratory infections reported in 18% of patients versus 13% in controls across rheumatoid arthritis studies.[1] Pneumonia specifically occurred at rates of 0.2-1.6% in Orencia-treated patients, depending on dose and combination therapy.[2]
What Do FDA Warnings Say About Infections?
The Orencia label warns of increased serious infections, including pneumonia, tuberculosis reactivation, and opportunistic infections like Pneumocystis jirovecii pneumonia (PJP). Risk rises with concurrent TNF blockers or corticosteroids. Prescribers must screen for latent TB and fungal infections before starting.[1][3]
How Common Are Lung Infections in Real-World Use?
In observational studies, Orencia users had a 1.5-2-fold higher pneumonia risk than the general population, though lower than some TNF inhibitors like infliximab. A Swedish registry of 13,000+ RA patients found Orencia's adjusted incidence rate ratio for serious infections at 1.4 (95% CI 1.2-1.7), with respiratory infections prominent.[4] COVID-19 era data noted no disproportionate lung severity versus other biologics.[5]
Who Faces Higher Risk?
Patients over 65, those with COPD, diabetes, prior lung disease, or on steroids/combo immunosuppressants see amplified risk—up to 4-fold for serious infections. Hypersensitivity pneumonitis is rare (<0.1%) but documented in case reports.[1][2]
How Does Orencia Compare to Other RA Drugs?
| Drug | Pneumonia Risk (vs. placebo) | Notes |
|------|------------------------------|-------|
| Orencia | 1.3-2.0x | Lower than TNFs; monitor prophylaxis for PJP if high-risk. |
| Humira (adalimumab) | 2.5-4x | Higher overall infection rate. |
| Xeljanz (tofacitinib) | 2-3x | Oral JAK inhibitor elevates herpes zoster too. |
| Methotrexate (non-biologic) | 1.2x | Baseline comparator; additive with Orencia. |
Orencia's risk profile is moderate among biologics.[4][6]
What Should Patients Watch For and Do?
Symptoms like persistent cough, fever, dyspnea, or chest pain warrant immediate medical attention. Vaccinate against pneumococcus, influenza, and COVID-19 before/during therapy (avoid live vaccines). Report infections promptly; treatment may pause Orencia.[1][3]
[1]: Orencia Prescribing Information (FDA)
[2]: ClinicalTrials.gov summaries for Orencia RA trials (e.g., AIM, ATTAIN)
[3]: FDA Post-Marketing Experience
[4]: Annals of the Rheumatic Diseases (Swedish registry, 2020)
[5]: Rheumatology (Oxford) COVID-19 biologics analysis, 2021
[6]: Cochrane Review on biologics in RA infections, 2017